As widely expected in the industry, Göran Ando has been appointed CEO of Slough, UK-based Celltech, replacing Peter Fellner, who will serve as the company’s chairman. Ando joins the company from Pharmacia, which was recently acquired by Pfizer, where he was president of R&D and an executive vice president. Previously, he was R&D director for Glaxo Group Research. He also held positions at Astra Research Centre, Bristol-Myers International Group, and Pfizer. Ando has an MD from Linkoping Medical University in Sweden.
Kevin Ryan has become president and CEO of Large Scale Biology. He replaces Robert Erwin as CEO, who will remain with the company as chairman of the board and head of its scientific advisory board, and John Fowler as president, who will remain a director of LSBC through the current term. Fowler will join Baycrest Capital, a private investment firm. LSBC’s senior vice president and CFO Ronald Artale has also become COO. Ryan already held the position of LSBC’s president from 1991 until 1995, when he became CEO of contact lens manufacturer Wesley Jessen.
Miraculins of Winnipeg, Manitoba, has appointed Kenneth Standing and Werner Ens as founding members of its scientific advisory board. Standing is professor emeritus in the department of physics at the University of Manitoba. He holds a BSc from the University of Manitoba and a PhD from Princeton University. Ens is also a professor in the department of physics, as well as the co-director of the Manitoba Centre for Proteomics. He holds a PhD in physics from the University of Manitoba. Standing and Ens jointly run the university’s Time-of-Flight Mass Spectrometry Laboratory.
One day after Celltech declared its offer for Oxford GlycoSciences unconditional (see p.1), Raymond Dwek, Max Burger, and Donald Drakeman resigned from the board of OGS. The same day, the company appointed
Peter Allen
, John Slater, Peter Nicholls, Ian Nicholson, Jonathan Glenn and Andrew Weir as non-executive directors to its board.